fludarabine has been researched along with Diathesis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arroyo, DS; Bussi, C; Heller, V; Iribarren, P; Rodriguez, CM; Sastre, D; Slavutsky, I; Stanganelli, C | 1 |
| Annechini, G; Capria, S; D'Elia, GM; De Angelis, F; Foà, R; Pulsoni, A; Russo, E; Stefanizzi, C; Tosti, ME | 1 |
| Asaka, M; Endo, T; Hashino, S; Imamura, M; Kahata, K; Koike, T; Kondo, T; Nishio, M; Okada, K; Onozawa, M; Ota, S; Sato, N; Shigematsu, A; Sugita, J; Takahata, M; Tanaka, J; Yamamoto, S; Yasumoto, A | 1 |
| Andritsos, L; Bechtel, T; Benson, DM; Blum, W; Byrd, JC; Devine, SM; Elder, P; Garzon, R; Hamadani, M; Hofmeister, C; Klisovic, R; Krugh, D; Lin, T; Marcucci, G; O'Donnell, L; Penza, S; Phillips, G | 1 |
| Bond, R; Brown, M; Campbell, P; Grigg, AP; Ritchie, D; Scarlett, J; Seymour, JF; Tam, C; Underhill, C | 1 |
1 trial(s) available for fludarabine and Diathesis
| Article | Year |
|---|---|
Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
Topics: Adult; Aged; Animals; Anti-Infective Agents; Antilymphocyte Serum; Busulfan; Disease Susceptibility; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Immunosuppressive Agents; Infection Control; Infections; Male; Medical Audit; Methotrexate; Middle Aged; Myeloablative Agonists; Patient Isolation; Postoperative Complications; Rabbits; T-Lymphocytes; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2009 |
4 other study(ies) available for fludarabine and Diathesis
| Article | Year |
|---|---|
Effects of rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Disease Susceptibility; Female; Flow Cytometry; Gene Expression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mutation; Sirolimus; Treatment Outcome; Vidarabine | 2019 |
Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease Susceptibility; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; IgG Deficiency; Immunocompromised Host; Immunotherapy; Incidence; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pneumonia; Prednisone; Proportional Hazards Models; Retrospective Studies; Rituximab; Transplantation, Autologous; Vidarabine; Vincristine; Young Adult | 2015 |
Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antigens, Viral; Bone Marrow Transplantation; Busulfan; Cytomegalovirus Infections; Disease Susceptibility; Female; Humans; Immunosuppressive Agents; Incidence; Intestinal Mucosa; Japan; Male; Middle Aged; Myeloablative Agonists; Postoperative Complications; Radiation Injuries; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation; Young Adult | 2009 |
Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Disease Susceptibility; Female; Herpesviridae Infections; Humans; Immunocompromised Host; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pneumonia, Pneumocystis; Risk; Rituximab; Vidarabine | 2005 |